Rights and obligations of an agreement pursuant to which the taxpayer paid a “break fee” terminating a proposed merger were in the nature of services, the court held, denying the IRS’s ...

Two sustained-release procedural pharmaceuticals or drug-delivery options are available in the US: the bimatoprost intracameral implant (Durysta; AbbVie) and the travoprost intracameral implant (iDose ...

Amplify CWP Growth & Income ETF earns a Strong Buy rating, while NEOS NASDAQ-100 High Income ETF earns just a Buy rating.

ASCO discussant Krina Patel, MD, of the University of Texas MD Anderson Cancer Center in Houston, noted, "Ciltacabtagene ...

CHICAGO -- Hitting rheumatoid arthritis (RA) early and hard, with targeted therapies as first-line treatment, appears to ...

For the third straight quarter, AbbVie has jacked up its revenue forecast for 2025. The Illinois drugmaker has raised its guidance by $400 million, now expecting sales to reach $60.9 billion. | ...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today ...

For its third quarter, AbbVie reaped just under $15.78 billion in revenue, which was 9% higher on a year-over-year basis. This was led by the company's enviable collection of blockbuster drugs; ...

A long-awaited definition of Islamophobia is expected within weeks - and a former faith minister is urging the government to adopt it in full. It is expected that the government will move away from ...

In the latest close session, AbbVie (ABBV) was down 1.17% at $228.68. The stock fell short of the S&P 500, which registered a loss of 0.53% for the day. Meanwhile, the Dow lost 0.71%, and the Nasdaq, ...

LOS ANGELES CAPITAL MANAGEMENT LLC increased its position in AbbVie by 304,281 shares during Q3 2025, an estimated $61.96 million trade based on the average price for Q3 2025, according to its October ...